Compare BSL & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSL | IPHA |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.0M | 189.5M |
| IPO Year | N/A | N/A |
| Metric | BSL | IPHA |
|---|---|---|
| Price | $12.92 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 29.9K | ★ 135.6K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 9.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.45 | $1.18 |
| 52 Week High | $14.35 | $2.63 |
| Indicator | BSL | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 36.90 | 52.09 |
| Support Level | $12.76 | $1.72 |
| Resistance Level | $12.98 | $1.82 |
| Average True Range (ATR) | 0.12 | 0.21 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 19.05 | 34.23 |
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.